Overbeck, Tobias R.

[["dc.bibliographiccitation.firstpage","270"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Oncology"],["dc.bibliographiccitation.lastpage","278"],["dc.bibliographiccitation.volume","93"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Arnemann, Johanna"],["dc.contributor.author","Waldmann-Beushausen, Regina"],["dc.contributor.author","Schöndube, Friedrich A."],["dc.contributor.author","Reuter-Jessen, Kirsten"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Trümper, Lorenz"],["dc.date.accessioned","2019-01-29T11:57:51Z"],["dc.date.available","2019-01-29T11:57:51Z"],["dc.date.issued","2017"],["dc.description.abstract","ATP-binding cassette transport protein A3 (ABCA3) is expressed in non-small cell lung cancer (NSCLC). We hypothesize that high-level ABCA3 expression may have a negative prognostic impact in patients with NSCLC."],["dc.identifier.doi","10.1159/000477619"],["dc.identifier.pmid","28683465"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/57421"],["dc.language.iso","en"],["dc.notes.intern","DeepGreen Import"],["dc.notes.status","final"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1423-0232"],["dc.relation.issn","0030-2414"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","ABCA3 Phenotype in Non-Small Cell Lung Cancer Indicates Poor Outcome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","362"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Oncology"],["dc.bibliographiccitation.lastpage","370"],["dc.bibliographiccitation.volume","84"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Hupfeld, Timo"],["dc.contributor.author","Krause, Doris"],["dc.contributor.author","Waldmann-Beushausen, Regina"],["dc.contributor.author","Chapuy, Björn"],["dc.contributor.author","Guedenzoph, Bjoern"],["dc.contributor.author","Aung, Thiha"],["dc.contributor.author","Inagaki, Nobuya"],["dc.contributor.author","Schoendube, Friedrich Albert"],["dc.contributor.author","Danner, Bernhard Christoph"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Wulf, Gerald G."],["dc.date.accessioned","2018-11-07T09:29:56Z"],["dc.date.available","2018-11-07T09:29:56Z"],["dc.date.issued","2013"],["dc.description.abstract","Patients with advanced-stage bronchial cancer benefit from systemic cytostatic therapy, in particular from regimens integrating cisplatin and taxanes. However, eventual disease progression leads to a fatal outcome in most cases, originating from tumor cells resisting chemotherapy. We here show that the intracellular ATP-binding cassette transporter A3 (ABCA3), previously recognized as critical for the secretion of surfactant components from type 2 pneumocytes, is expressed in non-small-cell lung cancer (NSCLC) cells. With some heterogeneity in a given specimen, expression levels detected immunohistochemically in primary cancer tissue were highest in adenocarcinomas and lowest in small cell lung cancers. Genetic silencing of ABCA3 in the NSCLC cell line models A549, NCI-H1650 and NCI-H1975 significantly increased tumor cell susceptibility to the cytostatic effects of both cisplatin (in all cell lines) and paclitaxel (in two of three cell lines). Taken together, ABCA3 emerges as a modulator of NSCLC cell susceptibility to cytostatic therapy. Copyright (c) 2013 S. Karger AG, Basel"],["dc.description.sponsorship","Faculty of Medicine, Georg August University Gottingen, Germany"],["dc.identifier.doi","10.1159/000348884"],["dc.identifier.isi","000320219100007"],["dc.identifier.pmid","23689165"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10826"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31175"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0030-2414"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Intracellular ATP-Binding Cassette Transporter A3 is Expressed in Lung Cancer Cells and Modulates Susceptibility to Cisplatin and Paclitaxel"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","424"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Schaefer, Inga-Marie"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Schweyer, Stefan"],["dc.contributor.author","Menke, Jan"],["dc.date.accessioned","2018-11-07T09:05:44Z"],["dc.date.available","2018-11-07T09:05:44Z"],["dc.date.issued","2012"],["dc.description.abstract","Background: Pulmonary carcinosarcoma is a biphasic tumour with an unfavourable prognosis. The differential diagnosis includes pulmonary blastoma and is often challenging. Case presentation: We here describe a case of blastomatoid pulmonary carcinosarcoma in a 58-year-old patient, who underwent surgical resection. Histopathological examination revealed immature glandular epithelium resembling high-grade fetal adenocarcinoma expressing epithelial markers and membranous beta-catenin, and blastomatoid spindle cells with partial rhabdomyosarcoma-like differentiation. Both elements expressed p53, MDM2, and cyclin-dependent kinase 4 (CDK4), but not thyroid-transcription factor 1 (TTF-1). Mutation analysis of KRAS, EGFR, and beta-catenin revealed no mutations. Comparative genomic hybridization detected +1q, +6p, +6q24qter, +8q, +11q12q14, +11q23qter, +12q12q21, +12q24qter, +17q, +20q, -5q14q23, -9p13pter, -13q21q21, and amplifications at 12q14q21, 15q24qter, 20q11q12. Conclusion: The observed molecular and cytogenetic findings may provide additional tools for the differential diagnosis of biphasic pulmonary neoplasms. Furthermore, TP53, MDM2, CDK4, and PTPN1 may be involved in tumourigenesis."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2012"],["dc.identifier.doi","10.1186/1471-2407-12-424"],["dc.identifier.isi","000312100800001"],["dc.identifier.pmid","23006472"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8423"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25394"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2407"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Blastomatoid pulmonary carcinosarcoma: report of a case with a review of the literature"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","179"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Dermatology"],["dc.bibliographiccitation.lastpage","182"],["dc.bibliographiccitation.volume","225"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T09:14:44Z"],["dc.date.available","2018-11-07T09:14:44Z"],["dc.date.issued","2012"],["dc.description.abstract","Erlotinib inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR) and is successfully used in lung cancer treatment. EGFR is essential in skin development and function and may have a role in the pathogenesis of psoriasis. Cutaneous side effects are very common in patients treated with erlotinib, and therapeutic use of erlotinib in dermatological disorders has therefore not been considered. We report two cases of patients with lung cancer and concomitant psoriasis treated with erlotinib with complete resolution of the skin problems. We present a review of the current literature on the topic. Copyright (C) 2012 S. Karger AG, Basel"],["dc.description.sponsorship","Roche"],["dc.identifier.doi","10.1159/000342786"],["dc.identifier.isi","000311760700015"],["dc.identifier.pmid","23095682"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/9078"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27489"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","1018-8665"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Two Cases of Psoriasis Responding to Erlotinib: Time to Revisiting Inhibition of Epidermal Growth Factor Receptor in Psoriasis Therapy?"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Public Health"],["dc.bibliographiccitation.volume","10"],["dc.contributor.affiliation","Schröder, Dominik; 1Department of General Practice, University Medical Center, Göttingen, Germany"],["dc.contributor.affiliation","Heesen, Gloria; 1Department of General Practice, University Medical Center, Göttingen, Germany"],["dc.contributor.affiliation","Heinemann, Stephanie; 1Department of General Practice, University Medical Center, Göttingen, Germany"],["dc.contributor.affiliation","Hummers, Eva; 1Department of General Practice, University Medical Center, Göttingen, Germany"],["dc.contributor.affiliation","Jablonka, Alexandra; 2Department of Rheumatology and Immunology, Hannover Medical School, Hanover, Germany"],["dc.contributor.affiliation","Steffens, Sandra; 2Department of Rheumatology and Immunology, Hannover Medical School, Hanover, Germany"],["dc.contributor.affiliation","Mikuteit, Marie; 2Department of Rheumatology and Immunology, Hannover Medical School, Hanover, Germany"],["dc.contributor.affiliation","Niewolik, Jacqueline; 2Department of Rheumatology and Immunology, Hannover Medical School, Hanover, Germany"],["dc.contributor.affiliation","Overbeck, Tobias R.; 4Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Kallusky, Jonathan; 4Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Müller, Frank; 1Department of General Practice, University Medical Center, Göttingen, Germany"],["dc.contributor.author","Schröder, Dominik"],["dc.contributor.author","Heesen, Gloria"],["dc.contributor.author","Heinemann, Stephanie"],["dc.contributor.author","Hummers, Eva"],["dc.contributor.author","Jablonka, Alexandra"],["dc.contributor.author","Steffens, Sandra"],["dc.contributor.author","Mikuteit, Marie"],["dc.contributor.author","Niewolik, Jacqueline"],["dc.contributor.author","Kallusky, Jonathan"],["dc.contributor.author","Müller, Frank"],["dc.contributor.author","Overbeck, Tobias R."],["dc.date.accessioned","2022-04-26T12:34:44Z"],["dc.date.available","2022-04-26T12:34:44Z"],["dc.date.issued","2022"],["dc.date.updated","2022-05-10T16:09:22Z"],["dc.description.abstract","Background: Restrictions to contain the COVID-19 pandemic affect the social participation of people worldwide. Especially those at high risk for a severe disease tend to abstain from social gatherings. While there are a few questionnaires to measure social participation in elderly or chronic patients, a valid survey instrument that includes pandemic-related social participation is needed. Methods We developed a social participation questionnaire that aims to assess pandemic-related restrictions in social participation. Items were developed using a theory and literature-based approach and then compiled in a discursive process involving experts and lay people. This was followed by the validation of the questionnaire through a cross-sectional survey on 431 individuals. Items with low item-total correlations and low factor loadings using exploratory factor analysis [EFA] were excluded. Using EFA on the remaining items, the factor structure was retrieved and tested with a confirmatory factor analysis [CFA]. Internal consistency was assessed with Chronbachs α. Results Initially, 27 items were developed which were used for validation. 13 items were excluded due to low item-total correlations and factors loadings. EFA of the remaining 14 items revealed three factors which were identified as domains “active social participation,” “wellbeing,” and “restrictions”. CFA showed an acceptable model fit using the three-dimensional structure. Chronbachs α of 0.81 and McDonalds Ω of 0.87 indicate good internal consistency. Correlation analysis showed an association between the developed questionnaire and previously-established participation and mental health scales. Conclusion This study suggests that our 14 item questionnaire is of high reliability and validity and can be used to measure social participation during a pandemic."],["dc.identifier.doi","10.3389/fpubh.2022.831087"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/106769"],["dc.language.iso","en"],["dc.publisher","Frontiers Media S.A."],["dc.relation","DEFEnse Against COVID-19 STudy"],["dc.relation.issn","2296-2565"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights.uri","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Development and Validation of a Questionnaire to Assess Social Participation of High Risk-Adults in Germany During the COVID-19 Pandemic"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","403"],["dc.bibliographiccitation.firstpage","403"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Infectious Diseases"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Dopfer-Jablonka, Alexandra"],["dc.contributor.author","Steffens, Sandra"],["dc.contributor.author","Müller, Frank"],["dc.contributor.author","Mikuteit, Marie"],["dc.contributor.author","Niewolik, Jacqueline"],["dc.contributor.author","Cossmann, Anne"],["dc.contributor.author","Stankov, Metodi V."],["dc.contributor.author","Behrens, Georg M. N."],["dc.contributor.author","Hummers, Eva"],["dc.contributor.author","Heesen, Gloria"],["dc.contributor.author","Schröder, Dominik"],["dc.contributor.author","Roder, Sascha"],["dc.contributor.author","Klawonn, Frank"],["dc.contributor.author","Vahldiek, Kai"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Kallusky, Jonathan"],["dc.contributor.author","Falk, Christine S."],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Heinemann, Stephanie"],["dc.date.accessioned","2022-04-29T07:33:23Z"],["dc.date.accessioned","2022-08-12T12:57:45Z"],["dc.date.available","2022-04-29T07:33:23Z"],["dc.date.available","2022-08-12T12:57:45Z"],["dc.date.issued","2022-04-25"],["dc.date.updated","2022-07-29T12:00:25Z"],["dc.description.abstract","Background\r\n Immunocompromised people (ICP) and elderly individuals (older than 80 years) are at increased risk for severe coronavirus infections. To protect against serious infection with SARS-CoV-2, ICP are taking precautions that may include a reduction of social contacts and participation in activities which they normally enjoy. Furthermore, for these people, there is an uncertainty regarding the effectiveness of the vaccination. The COVID-19 Contact (CoCo) Immune study strives to characterize the immune response to COVID-19 vaccination in immunocompromised, elderly people, and patients with hematological or oncological diseases. The study uses blood-based screenings to monitor the humoral and cellular immune response in these groups after vaccination. Questionnaires and qualitative interviews are used to describe the level of social participation.\r\n \r\n \r\n Methods\r\n The CoCo Immune Study is a mixed methods prospective, longitudinal, observational study at two large university hospitals in Northern Germany. Starting in March 2021, it monitors anti-SARS-CoV-2 immune responses and collects information on social participation in more than 600 participants, at least 18 years old. Inclusion criteria and subcohorts: Participants with (1) regularly intake of immunosuppressive medication (ICP-cohort) or (2) age ≥ 80 years (80 + -cohort). Additionally, patients with current or former (3) myeloid, (4) lymphatic disease or (5) solid tumor under checkpoint inhibition (3–5: HO-cohort). Exclusion criteria: (1) refusal to give informed consent, (2) contraindication to blood testing, (3) inability to declare consent. Participants complete a questionnaire at four different time points: prior to full vaccination, and 1, 6 and 12 months after completed vaccination. In addition, participants draw blood samples themselves or through a local health care provider and send them with their questionnaires per post at the respective time points after vaccination. Patients of the HO cohort dispense additional blood samples at week 3 to 12 and at month 6 to 9 after 2nd vaccination to gain additional knowledge in B and T cell responses. Selected participants are invited to qualitative interviews about social participation.\r\n \r\n \r\n Discussion\r\n This observational study is designed to gain insight into the immune response of people with weakened immune systems and to find out how social participation is affected after COVID-19 vaccination.\r\n Trial registration: This study was registered with German Clinical Trial Registry (registration number: DRKS00023972) on 30th December 2020."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.citation","BMC Infectious Diseases. 2022 Apr 25;22(1):403"],["dc.identifier.doi","10.1186/s12879-022-07347-w"],["dc.identifier.pmid","35468758"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/106987"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112723"],["dc.language.iso","en"],["dc.relation","DEFEnse Against COVID-19 STudy"],["dc.relation.eissn","1471-2334"],["dc.relation.issn","1471-2334"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.subject","SARS-CoV-2"],["dc.subject","COVID-19"],["dc.subject","Pandemic"],["dc.subject","Humoral and cellular immunity"],["dc.subject","Immunocompromised people"],["dc.subject","Elderly"],["dc.subject","Hematology"],["dc.subject","Solid tumor"],["dc.subject","Checkpoint inhibition"],["dc.subject","Serological testing"],["dc.subject","Coronavirus"],["dc.subject","Social participation"],["dc.subject","Immunogenicity"],["dc.title","SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","961"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Journal of Cancer Research and Clinical Oncology"],["dc.bibliographiccitation.lastpage","967"],["dc.bibliographiccitation.volume","135"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Herrmann, Markus Karl Alfred"],["dc.contributor.author","Kertesz, Tereza"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T08:28:13Z"],["dc.date.available","2018-11-07T08:28:13Z"],["dc.date.issued","2009"],["dc.description.abstract","To evaluate toxicity of radiochemotherapy schedule using daily-low-dose-cisplatin in radiochemotherapy of locally-advanced head-and-neck-cancer (HNSCC). From October 2003 to October 2006, 50 patients with HNSCC (stage III/IVA/IVB) were treated. In 32 patients, surgery and adjuvant radiotherapy(64 Gy), in 18 patients definitive radiotherapy(70 Gy) was performed. Low-dose-cisplatin was applied concomitantly (6 mg/m(2)/every radiotherapy-day). Acute toxicity a parts per thousand yengrade 3 was observed in 22 patients (11 patients mucositis/dysphagia, 7 hematologic toxicity, 4 mucositis/dysphagia/hematologic toxicity). 90% of our patients received > 80% of the planned cumulative chemotherapy dose, 94% the intended dose of radiotherapy. After median follow-up of 24.2 months, 3-year overall survival and loco-regional control rates were 67.1 and 78%. During follow-up, chronic toxicity a parts per thousand yengrade 3 (xerostomia, subcutaneous fibrosis, or lymphedema) was observed in nine patients. We found chemoradiation with daily-low-dose-cisplatin to be feasible with advantage of low acute and chronic toxicity. Therefore, use of low-dose-cisplatin should be evaluated in future clinical trials."],["dc.identifier.doi","10.1007/s00432-008-0532-x"],["dc.identifier.isi","000266477900012"],["dc.identifier.pmid","19107519"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3539"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16373"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-1335"],["dc.relation.issn","0171-5216"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","749"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Clinical Pharmacology & Therapeutics"],["dc.bibliographiccitation.lastpage","757"],["dc.bibliographiccitation.volume","83"],["dc.contributor.author","Kuehne, Annett"],["dc.contributor.author","Sezer, Orhan"],["dc.contributor.author","Heider, Ulrike"],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Muhlke, Sabine"],["dc.contributor.author","Niere, W."],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Kaiser, R."],["dc.date.accessioned","2018-11-07T11:15:25Z"],["dc.date.available","2018-11-07T11:15:25Z"],["dc.date.issued","2008"],["dc.description.abstract","Melphalan is associated with severe side effects such as mucositis, diarrhea, and myelosuppression. We investigated how much the individual severity of these side effects is predicted by pharmacokinetics. In addition, we studied glutathione S-transferase GSTM1, GSTT1, and GSTP1 polymorphisms in relation to adverse events. A high interindividual pharmacokinetic variability was observed in 84 patients. There was a linear correlation between creatinine and melphalan clearance (P = 0.0004). Patients treated with a dose >= 70 mg/m(2) had a 23-fold increased risk to develop mucositis (P<0.001) and a 12-fold increased risk to develop diarrhea (P<0.001) compared with lower doses. The GSTP1 codon 105 polymorphism may be relevant for development of mucositis and the GSTT1 deletion may predict diarrhea, but these findings require confirmation. Melphalan-induced side effects were significantly dependent only on dose. Therapeutic drug monitoring or genotyping for GST does not appear to be very helpful in optimizing therapy with melphalan."],["dc.identifier.doi","10.1038/sj.clpt.6100336"],["dc.identifier.isi","000255288100023"],["dc.identifier.pmid","17914442"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6076"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54361"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","0009-9236"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","89"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Cancer Research and Clinical Oncology"],["dc.bibliographiccitation.lastpage","97"],["dc.bibliographiccitation.volume","136"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Gunawan, Bastian"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Herrmann, Markus Karl Alfred"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T08:47:54Z"],["dc.date.available","2018-11-07T08:47:54Z"],["dc.date.issued","2010"],["dc.description.abstract","Nasopharyngeal carcinomas (NPC) are radiosensitive, and radiotherapy is the standard curative treatment. Furthermore, it has been shown that combined radiochemotherapy improves prognosis in locally advanced stages. Further encouraging results have been obtained with adjuvant interferon-beta after primary radio(chemo)therapy in childhood undifferentiated NPC. Aim of the present study was to evaluate the treatment results after long-term follow-up after radio(chemo)therapy for adult NPC with special reference to patients with undifferentiated carcinomas treated with adjuvant interferon-beta. From 02/1992 to 07/2008, 26 adult patients with NPC without distant metastases were treated (17 squamous cell carcinomas, 9 undifferentiated carcinomas). The treatment concepts changed over the years: 13 patients were treated with radiotherapy alone, 13 patients received combined radiochemotherapy. Additionally, six patients with undifferentiated carcinomas were treated with adjuvant interferon-beta after radiochemotherapy for 6 months. After a median follow-up of 96 months, 17 patients remain alive. Collectively, our 5-year overall-survival and loco-regional control rates were 74% (radiochemotherapy 81%, radiotherapy alone 68.5%) and 87% (radiochemotherapy 100%, radiotherapy alone 72.7%), respectively. All treatment regimens used were feasible; especially, adjuvant interferon-beta was applied as provided without high grade toxicity. All patients with undifferentiated carcinomas treated with adjuvant interferon-beta stayed alive until the end of the follow-up. In summary, our data affirm that NPC in adults are curable by primary radio(chemo)therapy. Furthermore, our data indicate that adjuvant interferon-beta application in undifferentiated NPC in adults is feasible and shows promising results. Further prospective clinical trials are needed to finally establish adjuvant interferon beta in curative treatment of adult NPC."],["dc.identifier.doi","10.1007/s00432-009-0640-2"],["dc.identifier.isi","000271981600011"],["dc.identifier.pmid","19618214"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/4152"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21075"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0171-5216"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Nasopharyngeal carcinoma in adults: treatment results after long-term follow-up with special reference to adjuvant interferon-beta in undifferentiated carcinomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","167"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Palliative Care"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Koenig, Julia F. L."],["dc.contributor.author","Asendorf, Thomas"],["dc.contributor.author","Simon, Alfred"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Truemper, Lorenz"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Overbeck, Tobias R."],["dc.date.accessioned","2022-10-04T05:34:29Z"],["dc.date.available","2022-10-04T05:34:29Z"],["dc.date.issued","2022-09-28"],["dc.date.updated","2022-10-02T03:12:18Z"],["dc.description.abstract","Abstract\r\n \r\n Background\r\n The advance directive represents patients’ health care choices and fosters patients’ autonomy. Nevertheless, understanding patients’ wishes based on the information provided in advance directives remains a challenge for health care providers. Based on the ethical premises of positive obligation to autonomy, an advanced directive that is disease-centred and details potential problems and complications of the disease should help health care providers correctly understand patients’ wishes. To test this hypothesis, a pilot-study was conducted to investigate whether physicians could make the correct end-of-life decision for their patients when patients used a disease-centred advance directive compared to a common advance directive. \r\n \r\n \r\n Material and methods\r\n A randomised, controlled, prospective pilot study was designed that included patients with non-small cell lung cancer (NSCLC) stage VI from the Department of Haematology and Medical Oncology, University Medical Centre, Goettingen. Patients were randomised into intervention and control groups. The control group received a common advance directive, and the intervention group received a disease-centred advance directive. Both groups filled out their advance directives and returned them. Subsequently, patients were asked to complete nine medical scenarios with different treatment decisions. For each scenario the patients had to decide whether they wanted to receive treatment on a 5-point Likert scale. Four physicians were given the same scenarios and asked to decide on the treatment according to the patients’ wishes as stated in their advance directives. The answers by patients and physicians were then compared to establish whether physicians had made the correct assumptions.\r\n \r\n \r\n Results\r\n Recruitment was stopped prior to reaching anticipated sample target. 15 patients with stage IV NSCLC completed the study, 9 patients were randomised into the control group and 6 patients in the intervention group. A total of 135 decisions were evaluated. The concordance between physicians’ and patients’ answers, was 0.83 (95%-CI 0.71–0.91) in the intervention group, compared to 0.60 (95%-CI 0.48–0.70) in the control group, and the difference between the two groups was statistically significant (p = 0.005).\r\n \r\n \r\n Conclusion\r\n This pilot study shows that disease-centred advance directives help physicians understand their NSCLC patients’ wishes more precisely and make treatment choices according to these wishes.\r\n \r\n \r\n Trial registration\r\n The study is registered at the German Clinical Trial Register (no. DRKS00017580, registration date 27/08/2019)."],["dc.identifier.citation","BMC Palliative Care. 2022 Sep 28;21(1):167"],["dc.identifier.doi","10.1186/s12904-022-01057-5"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114312"],["dc.language.iso","en"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.subject","Advance directive"],["dc.subject","Palliative care"],["dc.subject","End-of-life decision making"],["dc.subject","Prospective pilot study"],["dc.title","“SpezPat”- common advance directives versus disease-centred advance directives: a randomised controlled pilot study on the impact on physicians’ understanding of non-small cell lung cancer patients’ end-of-life decisions"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]